Cargando…

Multicenter Study of Albuterol Use Among Infants Hospitalized with Bronchiolitis

INTRODUCTION: Although bronchiolitis is a common reason for infant hospitalization, significant heterogeneity persists in its management. The American Academy of Pediatrics currently recommends that inhaled albuterol not be used in routine care of children with bronchiolitis. Our objective was to id...

Descripción completa

Detalles Bibliográficos
Autores principales: Condella, Anna, Mansbach, Jonathan M., Hasegawa, Kohei, Dayan, Peter S., Sullivan, Ashley F., Espinola, Janice A., Camargo, Carlos A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Department of Emergency Medicine, University of California, Irvine School of Medicine 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5942012/
https://www.ncbi.nlm.nih.gov/pubmed/29760843
http://dx.doi.org/10.5811/westjem.2018.3.35837
_version_ 1783321393328291840
author Condella, Anna
Mansbach, Jonathan M.
Hasegawa, Kohei
Dayan, Peter S.
Sullivan, Ashley F.
Espinola, Janice A.
Camargo, Carlos A.
author_facet Condella, Anna
Mansbach, Jonathan M.
Hasegawa, Kohei
Dayan, Peter S.
Sullivan, Ashley F.
Espinola, Janice A.
Camargo, Carlos A.
author_sort Condella, Anna
collection PubMed
description INTRODUCTION: Although bronchiolitis is a common reason for infant hospitalization, significant heterogeneity persists in its management. The American Academy of Pediatrics currently recommends that inhaled albuterol not be used in routine care of children with bronchiolitis. Our objective was to identify factors associated with pre-admission (e.g., emergency department or primary care) use of albuterol among infants hospitalized for bronchiolitis. METHODS: We analyzed data from a 17-center observational study of 1,016 infants (age <1 year) hospitalized with bronchiolitis between 2011–2014. Pre-admission albuterol use was ascertained by chart review, and data were available for 1,008 (99%) infants. We used multivariable logistic regression to identify infant characteristics independently associated with pre-admission albuterol use. RESULTS: Half of the infants (n=508) received at least one albuterol treatment before admission. Across the 17 hospitals, pre-admission albuterol use ranged from 23–84%. In adjusted analysis, independent predictors of albuterol use were the following: age ≥2 months (age 2.0–5.9 months [odds ratio (OR) 2.09, 95% confidence interval (CI) {1.45–3.01}] and age 6.0–11.9 months [OR 2.89, 95% CI {1.99–4.19}]); prior use of a bronchodilator (OR 1.89, 95% CI [1.24–2.90]); and presence of wheezing documented in pre-admission chart (OR 3.94, 95% CI [2.61–5.93]). By contrast, albuterol use was less likely among those with ≥7 days since the start of breathing problem (OR 0.66, 95% CI [0.44–1.00]) and parent-reported fever (OR 0.75, 95% CI [0.58–0.96]). CONCLUSION: Variation in pre-admission albuterol use suggests that local practice had a strong influence on use, but that patient characteristics also influenced the decision. While we agree with current guidelines in recommending against albuterol for all infants with bronchiolitis, our understanding of possible subgroups of responders may improve through investigation of infants with the identified characteristics.
format Online
Article
Text
id pubmed-5942012
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Department of Emergency Medicine, University of California, Irvine School of Medicine
record_format MEDLINE/PubMed
spelling pubmed-59420122018-05-14 Multicenter Study of Albuterol Use Among Infants Hospitalized with Bronchiolitis Condella, Anna Mansbach, Jonathan M. Hasegawa, Kohei Dayan, Peter S. Sullivan, Ashley F. Espinola, Janice A. Camargo, Carlos A. West J Emerg Med Treatment Protocol Assessment INTRODUCTION: Although bronchiolitis is a common reason for infant hospitalization, significant heterogeneity persists in its management. The American Academy of Pediatrics currently recommends that inhaled albuterol not be used in routine care of children with bronchiolitis. Our objective was to identify factors associated with pre-admission (e.g., emergency department or primary care) use of albuterol among infants hospitalized for bronchiolitis. METHODS: We analyzed data from a 17-center observational study of 1,016 infants (age <1 year) hospitalized with bronchiolitis between 2011–2014. Pre-admission albuterol use was ascertained by chart review, and data were available for 1,008 (99%) infants. We used multivariable logistic regression to identify infant characteristics independently associated with pre-admission albuterol use. RESULTS: Half of the infants (n=508) received at least one albuterol treatment before admission. Across the 17 hospitals, pre-admission albuterol use ranged from 23–84%. In adjusted analysis, independent predictors of albuterol use were the following: age ≥2 months (age 2.0–5.9 months [odds ratio (OR) 2.09, 95% confidence interval (CI) {1.45–3.01}] and age 6.0–11.9 months [OR 2.89, 95% CI {1.99–4.19}]); prior use of a bronchodilator (OR 1.89, 95% CI [1.24–2.90]); and presence of wheezing documented in pre-admission chart (OR 3.94, 95% CI [2.61–5.93]). By contrast, albuterol use was less likely among those with ≥7 days since the start of breathing problem (OR 0.66, 95% CI [0.44–1.00]) and parent-reported fever (OR 0.75, 95% CI [0.58–0.96]). CONCLUSION: Variation in pre-admission albuterol use suggests that local practice had a strong influence on use, but that patient characteristics also influenced the decision. While we agree with current guidelines in recommending against albuterol for all infants with bronchiolitis, our understanding of possible subgroups of responders may improve through investigation of infants with the identified characteristics. Department of Emergency Medicine, University of California, Irvine School of Medicine 2018-05 2018-04-05 /pmc/articles/PMC5942012/ /pubmed/29760843 http://dx.doi.org/10.5811/westjem.2018.3.35837 Text en Copyright: © 2018 Condella et al. http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 4.0) License. See: http://creativecommons.org/licenses/by/4.0/
spellingShingle Treatment Protocol Assessment
Condella, Anna
Mansbach, Jonathan M.
Hasegawa, Kohei
Dayan, Peter S.
Sullivan, Ashley F.
Espinola, Janice A.
Camargo, Carlos A.
Multicenter Study of Albuterol Use Among Infants Hospitalized with Bronchiolitis
title Multicenter Study of Albuterol Use Among Infants Hospitalized with Bronchiolitis
title_full Multicenter Study of Albuterol Use Among Infants Hospitalized with Bronchiolitis
title_fullStr Multicenter Study of Albuterol Use Among Infants Hospitalized with Bronchiolitis
title_full_unstemmed Multicenter Study of Albuterol Use Among Infants Hospitalized with Bronchiolitis
title_short Multicenter Study of Albuterol Use Among Infants Hospitalized with Bronchiolitis
title_sort multicenter study of albuterol use among infants hospitalized with bronchiolitis
topic Treatment Protocol Assessment
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5942012/
https://www.ncbi.nlm.nih.gov/pubmed/29760843
http://dx.doi.org/10.5811/westjem.2018.3.35837
work_keys_str_mv AT condellaanna multicenterstudyofalbuteroluseamonginfantshospitalizedwithbronchiolitis
AT mansbachjonathanm multicenterstudyofalbuteroluseamonginfantshospitalizedwithbronchiolitis
AT hasegawakohei multicenterstudyofalbuteroluseamonginfantshospitalizedwithbronchiolitis
AT dayanpeters multicenterstudyofalbuteroluseamonginfantshospitalizedwithbronchiolitis
AT sullivanashleyf multicenterstudyofalbuteroluseamonginfantshospitalizedwithbronchiolitis
AT espinolajanicea multicenterstudyofalbuteroluseamonginfantshospitalizedwithbronchiolitis
AT camargocarlosa multicenterstudyofalbuteroluseamonginfantshospitalizedwithbronchiolitis